Abivax S.A. (ABVX)
$87.98+2.04%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV47.8%–288.9%
- Market cap
- $6.5B
- Beta
- -0.25
- P/E (TTM)
- -16.83
- IV-%ile
- 16
- IV ATM
- 63.1%
- Short % float
- 11.59%
- Days to cover
- 5.0
- SI change
- +13.4%
- 1W
- +1.11%
- 1M
- -17.51%
- vs SPY 1W
- +1.25%
- vs SPY 1M
- -20.02%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 9$85.69-2.26%
- RCUSSELLArcus Biosciences, Inc.$3.1BCRISISQ 17$24.41+0.09%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35+6.96%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-3.01%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95+2.37%
- AVTXSELLAvalo Therapeutics, Inc.$718MCRISISQ -10$13.65-1.42%
- ANNXSELLAnnexon, Inc.$659MCRISISQ -9$4.02-4.18%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-2.59%
- IMMXSELLImmix Biopharma, Inc.$515MCRISISQ 23$9.46-2.07%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 30
- VALUE
- 8
- GROWTH
- 77
- GARP
- 11
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-51.5%
REV YoY-
ROE-85.9%
EPS YoY-
ROA-76.3%
GROSS153
OP11950
NET17489
[VALUATION]
P/E TTM-16.83
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B17.23
P/FCF-
EV/EBITDA-23.37
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.33
ALTMAN Z-
CURR RATIO5.97
ND/EBITDA-
BETA-0.25
Company news
FAQ
- What is LOPJLB’s current signal on ABVX?
- LOPJLB’s latest quantitative signal on Abivax S.A. (ABVX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ABVX in?
- Abivax S.A. (ABVX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Abivax S.A. (ABVX) do?
- Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being eval…